Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12531899 | 1.00 | ATM (0.53) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL29401932 | 1.00 | ATM (0.53) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL13743302 | 1.00 | ATM (0.53) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL30278721 | 0.92 | MDM4 (0.48) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL30854615 | 0.92 | MDM4 (0.48) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL15674248 | 0.92 | MDM4 (0.48) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL15674468 | 0.92 | MDM4 (0.48) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL21838224 | 0.92 | MDM4 (0.52) | CASP3MDM4TP53 | |
| SCHEMBL12563729 | 0.92 | MDM4 (0.52) | CASP3MDM4TP53 | |
| SCHEMBL7984402 | 0.92 | MDM4 (0.52) | CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767811-B2 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767811-B2 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20060293536-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2006-12-28 | — | — | US | disclosed |
| US-7057038-B2 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | BRANDEIS UNIVERSITY (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1419125-A4 | KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | UNIV BRANDEIS (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050020849-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | DENG LI (US) | 2005-01-27 | — | — | US | disclosed |
| US-6743914-B2 | USING TERTIARY AMINE CATALYST | BRANDEIS UNIVERSITY | 2004-06-01 | — | — | US | disclosed |
| EP-1419125-A1 | KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | Brandeis University (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1305270-B1 | KINETIC RESOLUTIONS OF CHIRAL 2- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | UNIV BRANDEIS (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030166963-A1 | Kinetic resolutions of chiral 2-and 3-substituted carboxylic acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-04 | — | — | US | disclosed |
| US-6562967-B2 | Drug screening; purity | BRANDEIS UNIVERSITY | 2003-05-13 | — | — | US | disclosed |
| EP-1305270-A1 | KINETIC RESOLUTIONS OF CHIRAL 2- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | Brandeis University (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003011799-A1 | KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | BRANDEIS UNIVERSITY (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020165393-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | disclosed |
| US-20020151744-A1 | Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-17 | — | — | US | disclosed |
| WO-2002010096-A1 | KINETIC RESOLUTIONS OF CHIRAL 2- AND 3-SUBSTITUTED CARBOXYLIC ACIDS | BRANDEIS UNIVERSITY (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165393-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | ADH5, ADH1C, TST | ATM 3889/4885ALDH1A1 231/4885THRB 1061/4885 |
| US-20050020849-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | ADH5, ADH1C, TST | ATM 3767/4885ALDH1A1 154/4885THRB 367/4885 |
| US-20060293536-A1 | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids | ADH5, ADH1C, TST | ATM 3767/4885ALDH1A1 154/4885THRB 367/4885 |
| US-20030166963-A1 | Kinetic resolutions of chiral 2-and 3-substituted carboxylic acids | ADH5, ADH1C, TST | ATM 3865/4885ALDH1A1 225/4885THRB 1116/4885 |
| US-20020151744-A1 | Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids | ADH5, ADH1C, TST | ATM 3400/4885ALDH1A1 218/4885THRB 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.